Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
暂无分享,去创建一个
O. Nanni | M. Guidoboni | M. Petrini | L. Fiammenghi | A. Granato | L. Ridolfi | A. Riccobon | F. De Rosa | V. Ancarani | E. Pancisi | F. Tauceri | M. Framarini | J. Bulgarelli | G. Gentili | V. Soldati | Serena Cassan
[1] P. Ascierto,et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.
[2] O. Nanni,et al. Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience , 2017, Melanoma research.
[3] C. Figdor,et al. Dendritic Cell–Based Immunotherapy: State of the Art and Beyond , 2016, Clinical Cancer Research.
[4] A. Salama,et al. Updates in Therapy for Advanced Melanoma , 2016, Cancers.
[5] Josep Malvehy,et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. , 2012, European journal of cancer.
[6] M. Atkins,et al. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced an , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] N. Barth,et al. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment , 2015, Cancer biotherapy & radiopharmaceuticals.
[8] P. Ascierto,et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.
[9] E. Scarpi,et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients , 2013, Journal of Translational Medicine.
[10] R. Dillman,et al. Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy: A Randomized Phase II Trial of Dendritic Cells Versus Tumor Cells in Patients With Metastatic Melanoma , 2012, Journal of immunotherapy.
[11] T. Ashizawa,et al. Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial , 2012, Oncology reports.
[12] R. Elashoff,et al. Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I) , 2012, Annals of Surgical Oncology.
[13] B. Kroon. Surgery for Distant Metastatic Melanoma Improves Survival , 2012, Annals of surgical oncology.
[14] T. Whiteside. Disarming suppressor cells to improve immunotherapy , 2012, Cancer Immunology, Immunotherapy.
[15] E. Scarpi,et al. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome , 2011, Melanoma research.
[16] E. Levine,et al. Role of bacillus Calmette–Guérin in the treatment of advanced melanoma , 2011, Expert review of anticancer therapy.
[17] D. Ollila. A phase 2 trial of complete resection for stage IV melanoma , 2011, Cancer.
[18] V. Sondak,et al. A phase 2 trial of complete resection for stage IV melanoma , 2011, Cancer.
[19] D. Morton,et al. Does metastasectomy improve survival in patients with stage IV melanoma? a cancer registry analysis of outcomes , 2011, Journal of surgical oncology.
[20] G. Schuler. Dendritic cells in cancer immunotherapy , 2010, European journal of immunology.
[21] T. Whiteside. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression , 2010, Expert opinion on biological therapy.
[22] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Hauschild,et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.
[24] I. Svane,et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters , 2008, Cancer Immunology, Immunotherapy.
[25] Gavin P Dunn,et al. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.
[26] D. Morton,et al. Contemporary surgical treatment of advanced-stage melanoma. , 2004, Archives of surgery.
[27] J. Manola,et al. A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.
[28] D. Morton,et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] V. Sondak,et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.